The time course of cytotoxicity induction and the bystander effect of the rabbit cytochrome P450 4B1 ( cyp4B1 ) / 4 -ipomeanol ( 4 -IM ) or 2 -aminoanthracene ( 2 -AA ) pharmacogene therapy systems were investigated and compared with the herpes simplex virus type 1 thymidine kinase / ganciclovir ( HSV -tk / GCV ) system. Experiments were performed in rat 9L gliosarcoma cells stably expressing cyp4B1 ( 9L -4B1 ), HSV -tk ( 9L -tk ), or their egfp ( enhanced green fluorescent protein ) fusion genes. Cyp4B1 -mediated activation of 2 -AA showed a high cell killing efficiency within only 48 hours with an onset after already 15 minutes of prodrug exposure. Residual 9L -4B1 cells were mostly damaged sublethally upon 2 -AA treatment showing an S phase arrest by cell cycle analysis. 4 -IM treatment of 9L -4B1 cells generated an overall weaker cell killing, especially after prodrug exposure times of less than 48 hours. Residual cells surviving 4 -IM treatment showed a G2 / M arrest and restarted proliferation after prodrug treatment was stopped. HSV -tk / GCV pharmacogene therapy resulted in a slower cytotoxicity induction than cyp4B1 / 2 -AA treatment with a significantly lower cell killing efficiency after 24 and 48 hours. HSV -tk / GCV -mediated cytotoxicity was widely similar to the cytotoxicity induced by cyp4B1 / 4 -IM with the exception of a continuous 48 -hour prodrug exposure where 4 -IM treatment showed a significantly higher cell killing rate. Cells surviving HSV -tk / GCV suicide gene therapy were not viable and showed an S -phase arrest. Whereas HSV -tk / GCV induced a strong bystander effect, only moderate bystander cell death depending on cell -to -cell contact was demonstrated in 9L / 9L -4B1 cocultures upon 2 -AA treatment and was even absent with 4 -IM, thereby contrasting with earlier reports. The absence of a strong bystander effect may limit, on one hand, the overall utility of the cyp4B1 systems for cancer gene therapy. On the other hand, the weak bystander effect together with the fast induction of cytotoxicity may provide marked advantages for the use of the cyp4B1 systems as biosafety enhancers for gene marking or replacement studies and donor lymphocyte infusions after allogeneic bone marrow transplantation.
P harmacological gene therapy is based on the transfer of enzyme genes, which render transduced tumor cells selectively sensitive to prodrugs that are usually nontoxic. 1 It provides a promising new therapeutic strategy for the future treatment of cancer, 2 although first clinical trials employing retrovirus-mediated pharmacogene therapy with the herpes simplex virus type 1 thymidine kinase /ganciclovir (HSV-tk / GCV ) system did not show a major therapeutic success in brain tumor patients. 3 This was mostly due to the very low rate of retrovirus vector -mediated in vivo gene transfer. 3 However, temporary therapeutic responses after HSV-tk /GCV gene therapy were reported in some patients, and were probably caused by the bystander effect. The bystander effect describes the phenomenon that nontransduced tumor cells are killed along with transduced cells in close proximity by intercellular transfer of toxic prodrug metabolites. 4 -7 Because elimination of tumor cells by bystander cell killing can partly overcome the problem of a low gene transfer rate, the bystander effect appears to be essential for improvement of any tumor pharmacogene therapy.
Recently, a new prodrug -activating enzyme system based on the rabbit cytochrome P450 4B1 isozyme gene (cyp4B1 ) has been described for pharmacogene therapy of experimental brain tumors. 8 -10 This enzyme activates the prodrug 4 -ipomeanol (4 -IM ), a naturally occurring substituted furane, and the toxic metabolite is suggested to be a furane epoxide. 11, 12 It can also convert aromatic amines, such as 2 -aminoanthracene ( 2-AA ), probably to highly reactive unsaturated dialdehyde intermediates. For both activated drugs, DNA alkylation seems to be the main mechanism of toxicity. 13 Rainov et al 8 demonstrated that the cyp4B1 /4-IM or cyp4B1/ 2-AA pharmacogene therapy systems can generate a strong cytotoxicity for brain tumor cells in vitro and in vivo. The presence of a bystander effect was only demonstrated for cyp4B1 /2 -AA.
The aim of the present study was to further analyse the cytotoxic properties of cyp4B1-activated 2 -AA or 4 -IM in order to assess the therapeutic efficacy and usefulness of these enzyme /prodrug systems for future cancer treatment strategies. Therefore, we investigated the cell killing efficiency of 2-AA and 4 -IM in rat 9L gliosarcoma cells stably expressing cyp4B1 (9L -4B1 ) and compared it to the cytotoxicity of GCV in 9L -tk. Cell killing efficacy was determined in dependence on the exposure time of the various prodrugs, and cell cycle analyses were performed. We also studied the extent of the bystander effect of 4-IM or 2 -AA in 9L /9L -4B1 cocultures. Based on our findings, some new and promising applications of the cyp4B1 system in cancer treatment strategies are suggested.
Materials and methods

Cell culture
Rat gliosarcoma 9L cells 14 obtained from the UCSF Brain Tumor Therapy Center and derived cell lines (see below ) were cultured at 378C and 5% CO 2 in RPMI 1640 medium ( Biochrom, Berlin, Germany ) supplemented with 1 mM sodium pyruvate, 2 mM L -glutamine, 100 U / mL penicillin, 100 g /mL streptomycin, and 10% heatinactivated fetal calf serum (all supplements obtained from Biochrom ). Cell culture medium including the abovementioned supplements will be referred to as regular medium in the following. Suicide gene therapy studies were performed in 9L cells stably expressing cyp4B1 ( 9L -4B1 ), 8 HSV-tk 15 (9L -tk ), and the egfp (enhanced green fluorescent protein ) fusion genes cyp4B1 /egfp (9L-4B1 /EGFP) and egfp /HSV-tk ( 9L -tk / EGFP ). 10 The cell line 9L -4B1 /EGFP was generated by liposomal transfection of 9L cells with the plasmid p4b1 -egfp 8, 10 containing the cyp4B1/egfp fusion gene and the neomycin resistance gene with subsequent selection of single cell clones by G418 treatment ( 1 mg / mL; Life Technologies, Eggenstein, Germany ).
Dose / response evaluations
Various 9L cells ( 9L, 9L -4B1, 9L -4B1 / EGFP, 9L -tk, 9L -tk / EGFP ) were plated in six -well plates at a density of 4Â10 5 cells /well. 9L, 9L -4B1, and 9L -4B1 /EGFP cells were treated with varying concentrations of 2 -AA (range: 0.5 -100 g /mL; Sigma, Deisenhofen, Germany ) or 4-IM ( range: 0.5 -5 g /mL; provided by the Drug Synthesis Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treatment, NCI, Bethesda, MD ). 9L, 9L -tk, and 9L -tk / EGFP cells were treated with varying concentrations of GCV (range: 0.1 -250 g /mL; Cymeven 1 ; Roche Molecular Systems, Grenzach -Wyhlen, Germany ). As controls, 9L, 9L -4B1, 9L -4B1 / EGFP, 9L -tk, and 9L -tk /EGFP cells remained without prodrug treatment. After 48 hours, prodrug containing medium was removed, and the amount of surviving cells was determined with a Coulter Counter Z1 (Coulter, Krefeld, Germany ).
Resulting cell numbers were demonstrated in relation to untreated controls ( = 100% ), respectively.
Cell proliferation assays
In order to investigate the cytotoxic effects of 2-AA and 4 -IM, 9L -4B1 cells were plated in six -well plates at a density of 4Â10 5 cells/ well. After 24 hours, cells were treated with 5 g/mL (25 M) 2 -AA or 5 g/mL (30 M) 4 -IM. Similar experimental settings were carried out for 9L -tk cells with the exception that prodrug treatment was performed with 10 g/mL (39 M) GCV. Prodrug containing medium was removed after defined time periods between 15 minutes and 8 hours, and cells were further grown in medium without prodrugs for 1 or 2 days. As controls, cells were also grown continuously in prodrug containing medium for 1 or 2 days. In each case, cells were trypsinized after 1 or 2 days, respectively, and counted using a Coulter Counter Z1. Surviving cells were determined in relation to untreated control cell numbers ( =100% ). Cell number averages of up to five independent experiments were statistically evaluated (Student's t test for independent samples; SPSS for Windows 10.0; SPSS Software, Munich, Germany ) for significant differences between the various suicide gene therapy systems. Testing was performed for each period of prodrug exposure, and statistical significance was defined by P <.05.
Cell viability assays
For determining cytotoxic versus cytostatic effects in dependence on the length of prodrug exposure, treatment of 9L -4B1 and 9L -tk cells was performed as described above for the cell proliferation assay. After 1 day, surviving cells were trypsinized, counted, and replated on 100 -mm Petri dishes at a density of 5Â10 3 cells/dish in medium without prodrugs. Nine days later, colonies with a diameter >1 mm were counted after fixation with 80% ethanol and staining with Gram's Crystal violet (Merck, Darmstadt, Germany ).
Cell cycle analyses
For investigation of cell cycle profiles after different periods of prodrug treatment, 9L -4B1 and 9L -tk cells were processed as described above for the cell proliferation assay. After 1 day, trypsinized surviving cells and floating apoptotic cells in the corresponding supernatants were collected, fixed by addition of cold 80% ethanol, and stored at À 208C for at least 1 hour. Then, cells were pelleted, resuspended in PBS containing RNAse A ( 0.1 mg /mL ) and propidium iodide (PI; 50 g /mL ), and incubated for 1 hour at room temperature. Data of PI-stained cells were collected with a FACSCalibur (Becton Dickinson, Heidelberg, Germany ) and analysed with the Modfit LT software ( Becton Dickinson ).
Bystander cell killing
Cytotoxic assays determining cell survival. To evaluate bystander cell killing, cocultures of transduced ( 9L -4B1 ) and native 9L cells were performed. Different ratios of 9L / 9L -4B1 cells were plated in six -well plates at a total Cancer Gene Therapy Differential cyp4B1 -mediated cytotoxicity S Frank et al density of 4Â10 5 cells/well and subsequently incubated for 24 hours. Cells were then treated with 5 g /mL 2-AA (25 M ) or 4-IM (30 M) for 1 -6 days followed by determination of cell survival as described above for the cell proliferation assay. In order to study if bystander cell death is mediated by diffusion throughout the medium, corresponding numbers (4Â10 5 cells ) of 9L and 9L -4B1 cells were each separately plated on the bottom of six -well plates or on an inserted micropore membrane ( 0.4 m pore size; Corning Costar, Cambridge, MA ). Thereby, upper and lower cell layers were generated, which were isolated from each other but could exchange media. Prodrug treatment and determination of cell survival were carried out as described for the cocultures. (Table 1) : LD 40 for 2 -AA was 0.2 g /mL (1.04 M ), for 4 -IM 2.1 g/mL ( 12.5 M). In comparison, LD 40 for GCV treatment of 9L -tk /EGFP cells as determined by drug /response evaluation ( Fig 1C ) was 0.1 g /mL ( 0.39 M).
We also defined a cytotoxic index ( Table 1) for cyp4B1/ 2 -AA and HSV-tk /GCV by the ratio of corresponding LD 40 values in transduced and nontransduced cells. The cytotoxic index was determined to standardize the comparison of the cyp4B1/2 -AA and HSV-tk /GCV gene therapy systems. By using this index, cell line -specific differences of both systems are supposed to be minimalized. Only enzyme activity and specific drug -related cytotoxicity appear to be parameters of major influence. Thus, the fact that GCV treatment showed a 20Â higher cytotoxic index than 2 -AA treatment (2500 for GCV vs 125 for 2-AA; Table 1 ) suggested a higher cytotoxic potential of HSV-tk /GCV in comparison to cyp4B1 /2 -AA.
Profile of 2 -AA and 4 -IM cytotoxicity after different lengths of prodrug treatment
In order to further analyse the cytotoxic profiles of 2 -AA and 4 -IM in 9L-4B1 cells, numbers of surviving cells were determined after different lengths of prodrug treatment ( 15 minutes up to 8 hours ) followed by incubation in regular medium for a total of 1 (Fig 2A ) or 2 days ( Fig 2B ) . As controls, cells were continuously incubated in prodrug 
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Differential cyp4B1 -mediated cytotoxicity S Frank et al containing medium for 24 or 48 hours. As demonstrated in Figure 2A and B, treatment of 9L -4B1 cells with 2-AA for only 15 minutes already resulted in a significant cell killing rate. After only 30 minutes of treatment, 60% of surviving cells was determined after 1 day and 50% after 2 days of additional incubation in regular medium. In contrast, a significant cytotoxic effect was not detectable in 9L -4B1 cells after a 15 -or 30-minute treatment with 4-IM. In order Parallel experiments were performed using 9L -tk cells treated with 10 g / mL GCV ( 39 M ). Average percentages of up to five independent experiments are shown.
Differential cyp4B1 -mediated cytotoxicity S Frank et al to get a 60% cell survival with 4 -IM similar to that obtained by 30-minute 2 -AA exposure, a treatment period of at least 5 hours was necessary (Fig 2A ) .
The maximum cytotoxic effect by treatment with 2-AA was achieved after only 5 hours in prodrug containing medium ( 15% surviving cells), when cell survival was determined after 2 days of incubation in regular medium ( Fig 2B ) . Cell killing efficiency was only slightly increased by continuous 2 -AA treatment. In contrast, 4 -IM treatment of 9L-4B1 cells showed only a moderate cytotoxic effect after even 24 hours of prodrug exposure (Fig 2A ) . However, after continuous 4 -IM treatment for 48 hours, a similar cell killing efficiency was observed as with 2 -AA. Native 9L cells were not affected by continuous 4-IM or 2 -AA treatment over several days ( data not shown ).
In order to compare cytotoxic efficiencies of the cyp4B1/ 4 -IM, 2-AA, and HSV-tk / GCV systems, similar experimental settings were chosen for 9L -tk cells as described above for 9L -4B1. Whereas a cytotoxic effect was already evident in 9L -tk cells upon treatment with GCV for only 15 -30 minutes (78% surviving cells after 1 -2 additional days of incubation in regular medium ), 57% of 9L-tk cells was still alive after a continuous GCV treatment over 24 hours (Fig 2A ) ; 24-hour 2-AA treatment of 9L -4B1: 27% cell survival; 24 -hour 4 -IM treatment of 9L -4B1: 46% cell survival.
Statistical evaluation of differences in cell death induction by the various suicide gene therapy systems ( Table 2 ) strongly supported the tendency demonstrated in Figure 2 : The cyp4B1 /2 -AA and cyp4B1 /4 -IM systems showed only comparable cell killing efficiencies within the first day after treatment. After 2 days of observation, cytotoxic effects of cyp4B1/4 -IM were markedly weaker when prodrug treatment was shorter than 7 hours. Within 2 days, the cyp4B1/2-AA system was also able to induce a stronger cytotoxic effect than the HSV-tk /GCV system. Within only 1 day, differences in cell killing efficiency between these two systems were only significant when very short ( 30-60 minutes ) or continuous prodrug treatment was applied. Differences between the cyp4B1 /4 -IM and HSV-tk /GCV systems were in general less prominent. Only upon continuous prodrug treatment over 48 hours was 4-IM -induced cytotoxicity significantly stronger than that by GCV.
Performing cell viability assays to distinguish between cytotoxic and cytostatic effects, we observed that surviving 9L -tk cells are sublethally damaged already after only 2 hours of GCV treatment that they were unable to restart cell growth ( Table 3 ) . Similar results were obtained for surviving 9L -4B1 cells after continuous treatment with 2 -AA for 24 hours. Studying shorter 2 -AA exposure times, surviving 9L -4B1 cells displayed a marked proliferative and colonyforming activity. However, the cytotoxic effect of 2-AA treatment was still stronger than of 4 -IM treatment. Even after a 24 -hour treatment of 4 -IM, surviving cells were shown to form a significant number of colonies. Complete cell killing with no further colony -forming potential was only achieved with the cyp4B1 /4 -IM system after 3 days of treatment (data not shown).
Differences were also found by analysing cell cycle profiles in 9L -tk (Fig 3A and B ) and 9L -4B1 cells ( Fig 3C-E ) after prodrug treatment. Whereas GCV-treated 9L -tk cells as well as 2 -AA -treated 9L -4B1 cells displayed a cell cycle arrest in the S phase clearly detectable already after a 4 -to 6-hour treatment ( Table 4 ) , 4 -IMtreated 9L -4B1 cells showed a significant arrest in the G2 / Cancer Gene Therapy Figure 3G , 4 -IM -treated 9L -4B1 cells restarted cellular proliferation when incubated in medium without prodrug for 2 days after a continuous 24 -hour treatment.
Whereas the population of 9L -4B1 cells arrested in the G2 / M phase was smaller than immediately after treatment ( Fig 3E ) , the population in the S phase was markedly increased, indicating restarting cellular proliferation and cell cycle progression. The amount of cells in the sub -G0 / G1 phase as a correlate for apoptotic cell death was only slightly elevated. In contrast, most of 2 -AA -treated 9L -4B1 cells shifted to the sub -G0 / G1 phase after 2 days of incubation in regular medium following a 24 -hour prodrug treatment (Fig 3F ) . These cells were obviously apoptotic, thus confirming the results of the viability assays.
Bystander effect
The bystander effect in 9L /9L -4B1 cocultures was determined upon 4 -IM ( Fig 4A ) and 2 -AA treatment (Fig 4B ) . Different ratios of 9L / 9L -4B1 cells were plated at a cellular density ensuring cell -to -cell contact during treatment. As shown in Figure 4A , no significant bystander effect was detectable upon treatment with 4-IM as cell killing efficiency obviously correlated with the percentage of 9L-4B1 cells. Similar results were obtained after prolonged prodrug treatment for up to 6 days ( data not shown). In 
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Differential cyp4B1 -mediated cytotoxicity S Frank et al contrast, moderate bystander cell killing was observed upon treatment with 2 -AA ( Fig 4B ) as cell killing efficiency was markedly higher than it was expected from the percentage of cyp4B1-positive cells; e.g., a 9L /9L -4B1 ratio of 7:3 ( = 70% 9L and 30% 9L-4B1 cells ) resulted in killing of 70% of all cells. The moderate bystander effect observed with the cyp4B1/ 2 -AA system was shown to be dependent on direct cellular contacts between transduced and nontransduced cells. In an experimental setting where filter inserts allowed a metabolic exchange between 9L -4B1 and native 9L cells only by diffusion, no cytotoxic effects on 9L bystander cells were evident after treatment with 5 g/ mL 2-AA for up to 3 days ( Fig 5) . Cytotoxicity by cyp4B1 -mediated conversion of 2 -AA was shown in the same experimental setting by killing of two separated 9L -4B1 cell populations.
In another series of experiments to compare the bystander effects of the cyp4B1 and HSV-tk suicide gene therapy systems, we used 9L cells stably transduced with the egfp fusion genes of HSV-tk (9L -tk /EGFP cells ) and cyp4B1 ( 9L -4B1 /EGFP cells ). By using green fluorescent suicide gene -expressing cells, transduced and bystander cells can be easily distinguished from each other by FACS analysis. By combination with PI staining, it is also possible to determine the percentage of living and dead cells within the different populations of transduced or bystander cells. The cyp4B1/2 -AA system could not be investigated by this assay because 2-AA displays a high degree of autofluorescence which interferes with a FACS analysis.
Upon HSV-tk /GCV treatment, no significant numbers of surviving transduced cells were found after 3 -4 days ( Fig 6B ) . The bystander populations also died completely within 3 -8 days, depending on the amount of transduced cells (Fig 6D ) . The percentages of dead bystander cells with and without GCV treatment are shown in Figure 6G . 
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Regarding the cyp4B1 /4 -IM system, a maximum killing effect of transduced cells was found within 2-3 days ( Fig 6A ) . Interestingly, a slightly reduced survival of bystander cells was apparent after 2 days ( Fig 6C ) . This observation was confirmed when the amounts of dead bystander cells with and without 4 -IM treatment were compared with each other (Fig 6E ) . However, this slightly enhanced induction of bystander cell death appeared to be only transient because numbers of dead bystander cells with and without 4 -IM treatment became equal on day 3. Thus, a significant and lasting bystander effect as observed with HSV-tk /GCV was not detectable.
Discussion
In the present study, we tried to further characterize the kinetics and properties of prodrug-induced cytotoxicity of the cyp4B1 pharmacogene therapy system. Interestingly, two chemically different prodrugs, 4 -IM and 2 -AA, can be converted by cyp4B1 to cytotoxic metabolites. Although 4 -IM and 2 -AA are both presumed to kill cells by inducing DNA -protein crosslinks and strand breaks, 11 -13 these prodrugs appeared to differ markedly from each other regarding the time course and characteristics of cytotoxicity mediated by them. This became obvious when we studied induction of transduced and nontransduced ( = bystander ) cell death, changes in cell cycle profiles, and viability of surviving tumor cells after various lengths of prodrug exposure ranging from 15 minutes up to 48 hours. We compared cyp4B1 /2 -AA and cyp4B1/4-IM with HSV-tk / GCV, which represents the most widely used pharmacogene therapy system to date. From our findings, we expected to define various advantageous applications of the cyp4B1 systems for future gene therapy.
In case of 2 -AA and 4-IM treatment, the full extent of cytotoxic effects was found only after a 48 -hour observation period. Interestingly, almost maximal cell killing ( 15% surviving cells ) was already achieved when 9L -4B1 cells were treated for only 5 hours with 2 -AA. This was not observed upon 4-IM treatment where only a continuous prodrug exposure for 48 hours led to maximal cell killing. For GCV treatment, even continuous exposure over 48 hours still resulted in more than 25% surviving 9L-tk cells, thus confirming our earlier experience that HSV-tk -mediated cell killing is relatively slow and generates a full cytotoxic effect only after 3-4 days. 10 The observation that cyp4B1 -mediated complete cell killing occurred within only 48 hours suggests that cyp4B1-mediated cell killing may be widely independent of cellular proliferation. Otherwise, cell death should have occurred more protracted as it was observed for HSV-tk /GCVmediated cytotoxicity. The HSV-tk /GCV system is generally considered to be predominantly cytotoxic to proliferating cells because it interferes with DNA synthesis. 16, 17 The cell killing efficiency of 2-AA and 4 -IM treatment after various lengths of prodrug exposure generally appeared to differ from that observed with GCV. Differences between 4 -IM -and GCV-induced cytotoxicity were less prominent than differences between 2 -AA and GCV. When cell survival was determined after 1 day, 2 -AA induced, after short (30 -60 minutes ) and continuous ( 24 hours ) treatment, a significant stronger cell killing than GCV. When cell survival was determined after 2 days, all 2 -AA treatments of more than 1-hour length resulted in a significantly stronger cell killing than corresponding GCV treatments. Regarding cytotoxic differences between 4-IM and GCV, only continuous treatment over 48 hours showed a significantly stronger effect for 4 -IM (P=.009 ).
Interestingly, the relatively slow and moderate induction of cell death by HSV-tk /GCV is accompanied by a sublethal cell damage. This irreversible cell damage even occurred after relatively short periods of prodrug treatment. Although approximately 70% of cells was still alive 2 days after a 2 -hour treatment with GCV, the surviving cells were unable to divide and form colonies. As a functional correlate, cellular blockage in the S phase was demonstrated in GCV-treated 9L -tk cells by cell cycle analysis. Despite an obviously faster mode of cytotoxicity induction, similar viability results suggesting an irreversible cell damage were only found after continuous treatment with 2 -AA for 24 hours. These nonviable cells demonstrated an S -phase arrest. When the length of exposure to 2-AA was shortened, surviving cells showed an increasing proliferative activity. In case of 4-IM treatment, even a continuous prodrug exposure for 24 hours had no permanent cytotoxic effect on surviving 9L -4B1 cells, which displayed a marked cellular proliferation after removal of the prodrug. 4 -IMmediated cytotoxicity was accompanied by a significant arrest of 9L -4B1 cells in the G2 /M phase.
The differences in cell viability and cell cycle profiles of 9L -tk and 9L -4B1 cells in dependence on the prodrug used suggest different modes and degrees of cytotoxicity for activated GCV, 2 -AA, and 4 -IM. HSV-tk /GCV -mediated cytotoxicity appears to escape all cellular repair mechanisms, whereas these mechanisms may partly ( cyp4B1 /2-AA) or completely ( cyp4B1 /4 -IM ) overcome the induced DNA damage. After transfer of 9L -4B1 cells to regular medium, 4 -IM -treated cells appeared to show a cell cycle progression, whereas almost all 2-AA -treated 9L -4B1 cells were found in the sub -G0 /G1 phase as an indication of apoptotic cell death.
We also investigated the bystander effect of 2-AA and 4 -IM treatment in 9L /9L -4B1 cocultures. The bystander effect of a pharmacogene therapy system is of great importance for effective tumor cell killing because the transduction efficiency of most gene transfer systems, especially of retroviral vectors, appears to be very low in patients. 3 Interestingly, 2-AA and 4 -IM treatment resulted in different bystander effects within our experimental settings. A moderate bystander cell killing was demonstrated upon treatment with 2-AA. This bystander effect required a close cellular contact. Upon treatment with 4-IM, no significant long -lasting bystander effect was detectable. This observation was confirmed by two different assays. Whereas the cytotoxic assays with varying percentages of transduced and nontransduced cells did not show any enhanced bystander cell killing by 4-IM, the flow cytometric analyses, where transduced and nontransduced cells could be studied separately from each other, gave some hints for the presence Cancer Gene Therapy Differential cyp4B1 -mediated cytotoxicity S Frank et al of a transient weak bystander cell death. These results appeared to differ from the data reported by Rainov et al. 8 They found a stronger bystander cell killing upon 2 -AA treatment and also suggested a 4 -IM -induced bystander effect. This discrepancy may be explained by the fact that the authors 8 used different experimental settings for their bystander studies. Thus, they suggested the presence of a bystander effect induced by activated 4 -IM on the basis of DNA alkylation studies, and demonstrated DNA strand breaks in L210 leukemia cells cocultured with 9L -4B1 after treatment with 4-IM. These findings were thought to indicate the transfer of cytotoxic metabolites from transduced to nontransduced cells. However, demonstration of DNA alkylation does not necessarily represent the induction of cell death because L210 leukemia cells may be capable of regaining proliferative activity after prodrug exposure, probably due to cellular DNA repair mechanisms.
The observation that 2 -AA, but not 4-IM, induces a moderate bystander effect may also partly explain the differences in cytotoxic efficiencies between both prodrugs. The presence of a bystander effect certainly supports the overall cytotoxic outcome. It may reduce the influence of the cellular prodrug uptake on cytotoxic kinetics. The strong bystander effect of the HSV-tk /GCV 18, 19 system may also explain why only a 2-hour GCV treatment is sufficient to damage all 9L -tk cells sublethally. The strong bystander effect assures that the cytotoxic metabolites are sufficiently distributed among all target cells. An earlier report 20 has shown that toxic GCV metabolites occur within 2 hours of prodrug administration in bystander-competent cells. Thus, the bystander effect can certainly overcome negative influences by a varying or inefficient uptake of the prodrug GCV.
Summing up our findings, it has to be stated that the rabbit cyp4B1 enzyme gene system, combined with 2 -AA or 4 -IM treatment, does not seem to represent a superior alternative to other pharmacogene therapy systems, especially the HSV-tk /GCV system, for tumor treatment. Even other systems based on cytochrome P450 -mediated activation of prodrugs, e.g., the cyp2B1 /cylophosphamide or ifosfamide systems, 21 -23 appear to imply a greater potential for suicide cancer gene therapy. With the cyp2B1 system, a strong bystander effect without the necessity of direct intercellular contacts between transduced and nontransduced cells was found only after a 3 -hour treatment with cylophosphamide. 24 However, some aspects of the cyp4B1 pharmacogene therapy systems appear to be interesting and have a promising potential for other gene therapy approaches. The cyp4B1/2 -AA or 4 -IM system apparently represents the only enzyme/prodrug combination, which induces a differential bystander effect depending on the prodrug used. These enzyme /prodrug combinations may be clinically relevant in applications calling for a significant bystander effect, such as cancer gene therapy, but also for other approaches which require targeted killing of single transduced cells without elimination of nontransduced bystander cells. Possible applications for a bystander-free prodrug -activating enzyme gene include: (a ) combination with reporter genes for clinical gene marking experiments; (b ) combination with therapeutic genes in gene replacement approaches; and (c ) transduction of donor lymphocytes used for leukemia relapse prophylaxis and treatment after allogeneic bone marrow transplantation (allo -BMT ).
For gene marking and gene replacement approaches, the combination with a prodrug -activating system would increase the biological safety of the whole strategy. Unintentional side effects, such as malignant transformation of normal cells, could be controlled by prodrug treatment. The extent of induced cell killing would be restricted to transduced cells when a bystander-free system, such as the cyp4B1 /4-IM system, is used.
The transduction of donor lymphocytes with a prodrug -activating enzyme gene is an approach which is already undergoing clinical exploration. 25 -28 Donor lymphocyte infusions (DLI ) have a growing clinical impact after allo -BMT for the prophylaxis and prevention of relapses in patients with chronic myeloic leukemia. The basis for DLI is the induction of a graft -versus -leukemia effect. 29, 30 However, the parallel induction of a severe graft -versushost disease (GvHD ) represents a frequent and potentially lethal complication of this approach. Therefore, donor lymphocytes have been transduced with the HSV-tk gene in order to eliminate them by GCV treatment in case of severe GvHD. 31 -33 Regarding the fast induction of cytotoxicity by 4 -IM without significant bystander cell death, the application of the cyp4B1 /4 -IM system for transduction of DLI would offer some therapeutic advantages to the HSV-tk /GCV system in terms of a more efficient control of GvHD without interference with other immune cells by bystander effects. 
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